about
Designs of drug-combination phase I trials in oncology: a systematic review of the literatureA design for phase I trials in completely or partially ordered groups.Designs for phase I trials in ordered groups.Implementation of adaptive methods in early-phase clinical trials.Practical designs for Phase I combination studies in oncologyA comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Phase I/II adaptive design for drug combination oncology trialsSpecifications of a continual reassessment method design for phase I trials of combined drugs.Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.Continual reassessment method for partial ordering.Dose-finding design for multi-drug combinations.Extended model-based designs for more complex dose-finding studies.Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromesBayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingAdvances in Statistical Approaches Oncology Drug Development.Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.Adaptive designs for dual-agent phase I dose-escalation studies.A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.Bayesian optimal interval design for dose finding in drug-combination trials.A two-dimensional biased coin design for dual-agent dose-finding trials.A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.Comparison of Isotonic Designs for Dose-Finding.Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.Design issues in dose-finding Phase I trials for combinations of two agents.A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.A latent contingency table approach to dose finding for combinations of two agents.Escalation with overdose control for phase I drug-combination trials.Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
P2860
Q26996348-E4DE5858-A200-4AC0-AECD-FF0BA176F1AAQ30252706-7865D138-DCCC-4EB2-9B38-A71A5B9D6436Q30275947-250B5FC7-3E5E-4C68-A3C7-9AE990218A78Q30277243-215C8E8F-5EB4-476A-8A2D-C15B9F83D4A5Q30278669-CAD28651-99AD-4F98-9BE5-0E04168DBE5DQ30299951-20E1BF37-D43C-4FE1-942A-06FA79EA5E45Q30371414-7101E97C-BEF3-44CE-BF3C-26B269566D59Q30409168-9D8C7FF5-F4F6-464C-9624-DC87308A6F03Q30412231-FF9411BC-B342-457F-A3E1-C2EF258557B1Q30416647-4FA471B4-735C-4DE6-AFD9-1704FAC54C44Q30423577-1CC6BFE5-2CB7-4EDC-9781-F0363B9501E0Q30424392-41F346FD-028F-415E-A3C0-CD6849915A29Q30424442-DE506BEE-2706-440D-B352-47D0E5FD80D3Q30868533-60042E43-C386-445F-AB0A-0098C206BEDAQ35108694-6557188B-E0C9-4616-84DE-80D125D630F4Q35175343-9402CC87-4B2F-4759-89A9-7B820D596424Q35565672-7E02DA62-5CC3-4DA7-974D-62264BEB73C3Q36033877-84408361-E3BF-4C37-BD3F-E0196C31A6FFQ36295897-F0E1B6CC-E1F3-483C-BD4B-6BB2BF483813Q36621961-58349EFE-F3BC-492B-BA3D-A3798E84535AQ37478123-264F8659-DE4E-4A0F-B523-CFB44FC7EF47Q37552881-C7B4EE50-D76B-4B07-BF35-179840D4AAE0Q37737198-AD64B2A9-6156-4C22-B6C0-7BA8AB4C69D9Q38090897-A96483B2-7DA2-44A0-BEDD-E94C49B3FDB1Q39125629-54D2727D-7DD3-4BC0-B554-E1FDFBA90961Q40732630-31CA5F7F-AA18-4C83-AFBA-1286E5E51C76Q40749503-F04FED2F-9362-478D-A66B-29459825FAEAQ41241253-AC4609E5-5C38-4927-AB98-86F9B5B03EF4Q41545724-3BB0E864-7760-4B56-BE85-3969FF806DF2Q42049533-1B7C29B6-B5E3-4D3A-B581-CC96EB0284C7Q43134353-DFFC7702-0C2E-4373-B628-FF3BD8F61F35Q43409313-432D8E7C-8923-4CC4-BBA5-473AFA198F25Q44494502-05DD50B1-9C87-4A4A-B6A2-6ACBFDE15CDEQ45713082-5AC200B9-E1A5-4076-975F-0BC49592A330Q45834856-A249DAD3-2EC8-448E-AAF7-4CB36FD7497DQ51001194-3930A596-60B5-4703-8A21-B3F6DC1D39E0Q51016744-A579C676-23CB-4EC4-8B44-C57D76F60DB6Q51086024-9A2B5F06-0F4C-4759-8AB5-C29885567E47Q51221460-1D73FE78-DF3C-4FDB-9055-DF5D8B512F1CQ51491952-97201FED-3311-4DA2-B975-B57257E58A2B
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Designs for single- or multiple-agent phase I trials.
@ast
Designs for single- or multiple-agent phase I trials.
@en
type
label
Designs for single- or multiple-agent phase I trials.
@ast
Designs for single- or multiple-agent phase I trials.
@en
prefLabel
Designs for single- or multiple-agent phase I trials.
@ast
Designs for single- or multiple-agent phase I trials.
@en
P2860
P1433
P1476
Designs for single- or multiple-agent phase I trials.
@en
P2093
Mark R Conaway
Stephanie Dunbar
P2860
P304
P356
10.1111/J.0006-341X.2004.00215.X
P407
P577
2004-09-01T00:00:00Z